// App-Quantinova.ai

3728 : Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations

Researchers

Presenter

  • Wontak Kim

Principal Investigators

  • Katherine K. Soh

  • Ye Sol Lee

  • Peter Peterson

  • Clifford J. Whatcott

  • Adam Siddiqui-Jain

  • Steven Weitman

  • David J. Bearss

  • Steven L. Warner

Medical Centers

  • Tolero Pharmaceuticals, Inc., Lehi, UT

Locations

  • United States

Companies

  • Tolero Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • 5-Azacytidine

  • Mitoxantrone

  • Vidaza

  • Cytarabine liposomal

  • Venetoclax

  • Alvocidib hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved